OHDSI Estonia

Background 

The University of Tartu in Estonia has an active health informatics research group led by Professor Jaak Vilo, Associate Professor Raivo Kolde, Dr. Sulev Reisberg, and around 15 other researchers, PhD students, and developers. They are involved in various OHDSI/OMOP-related initiatives, including IMI EMIF, IMI EHDEN, IMI OPTIMA, IMI PIONEER, EMA DARWIN, and Teaming for Excellence TeamPerMed projects. The group has conducted numerous health studies, developed new OHDSI/OMOP tools, and more.

In Estonia, two SMEs, STACC and Quretec, have received EHDEN certification for conducting OMOP ETL, and other institutions, such as Tartu University Hospital, have initiated converting their data to OMOP CDM. The Estonian Biobank, which is part of the University of Tartu, is also adopting OMOP.

Given the increased activity in Estonia related to OHDSI/OMOP, it was decided in December 2023 to establish the national OHDSI Estonia node to enhance coordination of activities and improve communication both within Estonia and with OHDSI collaborators beyond the country's borders.

Objectives 

  1. Embrace OHDSI’s mission, vision, and values.
  2. Enhance communication within Estonia among national node members and externally with other OHDSI nodes and stakeholders, including the OHDSI European chapter.
  3. Coordinate and consolidate OHDSI/OMOP-related initiatives and tools within Estonia, such as mapping tables and coding lists.
  4. Advocate for and advance the utilization and proficiency of the OMOP common data model in Estonia.

Leading Organisation(s)

Lead Sulev Reisberg, Ph.D.

Co-lead Raivo Kolde Ph.D.

University of Tartu

Members

Name

Organisation

Sulev Reisberg

University of Tartu

Raivo Kolde

University of Tartu

Jaak Vilo

University of Tartu

Õie Renata Siimon

University of Tartu

Marek Oja

University of Tartu

Kerli Mooses

University of Tartu

Markus Haug

University of Tartu

Hendrik Šuvalov

University of Tartu

Harry-Anton Talvik

University of Tartu

Kunnar Kukk

University of Tartu

Sirli Tamm

University of Tartu

Maarja Pajusalu

University of Tartu

Andres Metspalu

University of Tartu

Lili Milani

University of Tartu

Priit Kleemann

University of Tartu

Sirje Lind

University of Tartu

Johannes Holm

TEHIK

Jarno Raid

Tartu University Hospital

Lenne-Triin Kõrgvee

Tartu University Hospital

Margus Jäger

Quretec

Kalev Koppel

STACC

Anders Eriksson

Metrosert

Liisa Loog

Metrosert

Data Partners

Data Source Name

Organisation

Data Type

# Patients

Link

RITA MAITT

University of Tartu

10% random sample from national health databases 2012-2019 (150K patients)

150K

https://health-informatics.cs.ut.ee

Estonian Biobank

University of Tartu

EHR of consent-based biobank, 200K participants

200K

https://genomics.ut.ee/en/content/estonian-biobank

CORIVA

University of Tartu

Data for about 85K Covid-19 cases and 340K random population controls followed up between 2018-2022

425K

https://health-informatics.cs.ut.ee

Tartu University Hospital, cancer center

Tartu University Hospital, cancer center

Most essential cancer-related data (MEDOC, the Minimal Essential Description Of Cancer) to OMOP (project "DIGItal Infrastructure for ONcology in Europe")

NA

https://www.kliinikum.ee/vahikeskus/teadus-ja-innovatsioon/

Publications

  • Oja M, Tamm S, Mooses K, Pajusalu M, Talvik HA, Ott A, Laht M, Malk M, Lõo M, Holm J, Haug M. Transforming Estonian health data to the Observational Medical Outcomes Partnership (OMOP) common data model: Lessons learned. JAMIA open. 2023 Dec 1;6(4):ooad100.

  • Mooses K, Vesilind K, Oja M, Tamm S, Haug M, Kalda R, Suija K, Tisler A, Meister T, Malk M, Uusküla A. The use of prescription drugs and health care services during the 6-month post-COVID-19 period. Scientific Reports. 2023 Jul 19;13(1):11638.

  • Gandaglia G, Pellegrino F, Golozar A, De Meulder B, Abbott T, Achtman A, Omar MI, Alshammari T, Areia C, Asiimwe A, Beyer K. Clinical characterization of patients diagnosed with prostate cancer and undergoing conservative management: a PIONEER analysis based on big data. European Urology. 2023 Jul 5.

  • Voss EA, Shoaibi A, Lai LY, Blacketer C, Alshammari T, Makadia R, Haynes K, Sena AG, Rao G, van Sandijk S, Fraboulet C. Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study. EClinicalMedicine. 2023 Apr 1;58.

  • Uusküla A, Oja M, Tamm S, Tisler A, Laanpere M, Padrik L, Nygard M, Reisberg S, Vilo J, Kolde R. Prevaccination Prevalence of Type-Specific Human Papillomavirus Infection by Grade of Cervical Cytology in Estonia. JAMA Network Open. 2023 Feb 1;6(2):e2254075-.

  • Yang C, Williams RD, Swerdel JN, Almeida JR, Brouwer ES, Burn E, Carmona L, Chatzidionysiou K, Duarte-Salles T, Fakhouri W, Hottgenroth A. Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: a multinational real-world cohort analysis. InSeminars in arthritis and rheumatism 2022 Oct 1 (Vol. 56, p. 152050). WB Saunders.

  • Künnapuu K, Ioannou S, Ligi K, Kolde R, Laur S, Vilo J, Rijnbeek PR, Reisberg S. Trajectories: a framework for detecting temporal clinical event sequences from health data standardized to the Observational Medical Outcomes Partnership (OMOP) Common Data Model. JAMIA open. 2022 Apr 1;5(1):ooac021.

How to contribute?

  • To join OHDSI Estonia, email This email address is being protected from spambots. You need JavaScript enabled to view it.

  • Optional: To get an OHDSI MSTeams account use this link; and here you can sign up for Working Groups.